<DOC>
	<DOCNO>NCT01408615</DOCNO>
	<brief_summary>This observational study examine safety efficacy profile Elonva ( corifollitropin alfa ) administer Korean woman undergo controlled ovarian stimulation ( COS ) combination gonadotropin-releasing hormone ( GnRH ) antagonist development multiple follicle assist reproductive technology ( ART ) program .</brief_summary>
	<brief_title>A Post Marketing Observational Study Safety Efficacy Elonva ( Corifollitropin Alfa ) General Practice ( P08165 )</brief_title>
	<detailed_description />
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Infertility , Female</mesh_term>
	<criteria>Women indication COS prior vitro fertilization ( IVF ) /intracytoplasmic sperm injection ( ICSI ) meet criterion mention current Korean ELONVA local label Hypersensitivity active substance excipients Tumors ovary , breast , uterus , pituitary hypothalamus Abnormal ( menstrual ) vaginal bleeding without known/diagnosed cause . Primary ovarian failure Ovarian cyst enlarge ovary A history OHSS A previous COS cycle result 30 follicle â‰¥ 11 mm measure ultrasound examination Basal antral follicle count &gt; 20 Fibroid tumor uterus incompatible pregnancy Malformations reproductive organ incompatible pregnancy Pregnancy Polycystic ovarian syndrome</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>